StreetInsider.com News Articles

JPMorgan Starts Rhythm Pharmaceuticals (RYTM) at Overweight

Mon, 27 Jul 2026 03:04:16 -0400

JPMorgan analyst Priyanka Grover initiates coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Overweight rating and a price target of $145.00.

The analyst comments: “Our OW thesis centers on Rhythm’s opportunity to grow Imcivree (setmelanotide) from a rare genetic obesity franchise into a more durable MC4R-pathway rare disease platform, driven by the newly launched acquired hypothalamic obesity (HO) indication (WW peak sales ~ $2.1B), where there is a significant unmet need. Imcivree’s recent expansion into acquired HO is an important inflection point that we expect to be a key near-term driver for the next chapter of growth for Rhythm. Along with

JPMorgan Starts Rhythm Pharmaceuticals (RYTM) at Overweight

Mon, 27 Jul 2026 03:04:16 -0400

JPMorgan analyst Priyanka Grover initiates coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Overweight rating and a price target of $145.00.

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Tue, 21 Jul 2026 08:00:00 -0400

BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 4, 2026 to report its second quarter 2026 financial results and provide a corporate update.

To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.

A recording of

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Tue, 21 Jul 2026 08:00:00 -0400

To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.

A recording of

Rhythm Pharmaceuticals (RYTM) Reiterated at Market Outperform by Citizens

Tue, 14 Jul 2026 04:13:50 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $155.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).

The analyst commented, "Our first endocrinologist survey suggests that Imcivree is off to a strong start in HO, and if our results are representative of the broader prescriber base, we think Imcivree total sales (RYTM does not expect to break out sales by indication) could have a strong beat this quarter. Recall, management reported 150 start forms from 110 prescribers in the first six weeks of its launch (3/19/26-4/30/26) representing ~25 forms/week and ~1 prescription/physician. Conservatively assuming the same run rate, there would

Rhythm Pharmaceuticals TRANSCEND trial results published in NEJM

Wed, 08 Jul 2026 17:07:13 -0400

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced that results from its Phase 3 TRANSCEND trial evaluating setmelanotide in patients with acquired hypothalamic obesity have been published in The New England Journal of Medicine.

The 52-week, randomized, double-blind, placebo-controlled trial enrolled 120 patients aged four years and older, randomized 2:1 to once-daily subcutaneous setmelanotide or placebo. Patients treated with setmelanotide achieved a mean BMI reduction of -16.5% from baseline, compared with a +3.3% change for placebo patients, representing a placebo-adjusted difference of -19.8% (p<0.0001). Eighty percent of patients on setmelanotide achieved a BMI reduction of 5% or greater at 52 weeks. Patients also

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

Wed, 08 Jul 2026 17:07:01 -0400

BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity have been published in The New England Journal of Medicine (NEJM).

The TRANSCEND study is the largest and longest placebo-controlled clinical trial ever conducted in patients with acquired hypothalamic obesity. The publication highlights robust improvements in weight and hunger achieved with

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

Wed, 08 Jul 2026 17:07:01 -0400

Rhythm Pharmaceuticals (RYTM) PT Raised to $141 at RBC Capital

Tue, 07 Jul 2026 08:00:26 -0400

RBC Capital analyst Lisa Walter raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $141.00 (from $137.00) while maintaining a Outperform rating.

Form 4 RHYTHM PHARMACEUTICALS, For: Jul 01 Filed by: Garfield Alastair

Thu, 02 Jul 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260702/26729007.html

Form 4 RHYTHM PHARMACEUTICALS, For: Jul 01 Filed by: Garfield Alastair

Thu, 02 Jul 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260702/26729007.html

This biotech stock is on TD Cowen's best smidcap ideas list

Wed, 01 Jul 2026 12:00:00 -0400

TD Cowen has named a rare disease drugmaker one of its top small- and mid-cap (smidcap) picks for 2026, arguing that an ongoing drug launch and a pipeline with commercial potential stretching well into the next decade make the stock meaningfully undervalued at current levels.

The bank reiterated a Buy rating on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a price target of $130, implying nearly 20% upside.

The bull case centers on Imcivree (setmelanotide), Rhythm's first-in-class melanocortin-4 receptor agonist, and in particular its recently approved use in hypothalamic obesity (HO).

The FDA cleared that label expansion in March 2026, opening what Rhythm estimates to

This biotech stock is on TD Cowen's best smidcap ideas list

Wed, 01 Jul 2026 12:00:00 -0400

The bank reiterated a Buy rating on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a price target of $130, implying nearly 20% upside.

The bull case centers on Imcivree (setmelanotide), Rhythm's first-in-class melanocortin-4 receptor agonist, and in particular its recently approved use in hypothalamic obesity (HO).

The FDA cleared that label expansion in March 2026, opening what Rhythm estimates to

Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: JEAN CHRISTOPHE

Thu, 25 Jun 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260625/26693748.html

Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: JEAN CHRISTOPHE

Thu, 25 Jun 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260625/26693748.html

Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: MCGIRR DAVID W J

Thu, 25 Jun 2026 18:08:00 -0400

si-local-file:///var/storage/secattach/20260625/26693747.html

Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: MCGIRR DAVID W J

Thu, 25 Jun 2026 18:08:00 -0400

si-local-file:///var/storage/secattach/20260625/26693747.html

Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: TETRAULT LYNN A.

Thu, 25 Jun 2026 18:07:00 -0400

si-local-file:///var/storage/secattach/20260625/26693745.html

Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: TETRAULT LYNN A.

Thu, 25 Jun 2026 18:07:00 -0400

si-local-file:///var/storage/secattach/20260625/26693745.html

Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: Arbuckle Stuart A

Thu, 25 Jun 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260625/26693738.html

Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: Arbuckle Stuart A

Thu, 25 Jun 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260625/26693738.html

Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: GOOD JENNIFER L

Thu, 25 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26693733.html

Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: GOOD JENNIFER L

Thu, 25 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26693733.html

Form 8-K RHYTHM PHARMACEUTICALS, For: Jun 24

Thu, 25 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260625/26693055.html

Form 8-K RHYTHM PHARMACEUTICALS, For: Jun 24

Thu, 25 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260625/26693055.html